The current M&A environment and its strategic implications for emerging biotherapeutics companies
The age of the blockbuster drug may have come and gone. With dwindling pipelines and increasing generic competition, pharmaceutical companies continue to create efficiencies through mergers and acquisitions (M&A). Increasingly, the pharmaceutical industry is turning to biotechnology companies to drive new product innovations. As part of this evolving paradigm, biotechnology companies with deep therapeutic product pipelines A€“ A€˜biotherapeutics' companies A€“ protected by sound intellectual property rights are becoming ever more attractive targets for M&A. This is likely due to the facts that biotherapies command high reimbursement rates due to high efficacy and reduced toxicity, and are less vulnerable to generic competition due to technical and regulatory barriers. As a result, M&A has offered high returns to investors in recent years at a time when public markets have declined. In order to attract a purchaser, small biotherapeutics companies must develop product pipelines in a strategic manner, defining the target markets accurately and patenting technologies needed to protect shares of those markets. This article discusses the strategic considerations a biotherapeutics company should make as part of its exit strategy, as well as examples of how those considerations are represented in the current pharmaceutical M&A landscape.
유료 다운로드의 경우 해당 사이트의 정책에 따라 신규 회원가입, 로그인, 유료 구매 등이 필요할 수 있습니다. 해당 사이트에서 발생하는 귀하의 모든 정보활동은 NDSL의 서비스 정책과 무관합니다.
원문복사신청을 하시면, 일부 해외 인쇄학술지의 경우 외국학술지지원센터(FRIC)에서
무료 원문복사 서비스를 제공합니다.
NDSL에서는 해당 원문을 복사서비스하고 있습니다. 위의 원문복사신청 또는 장바구니 담기를 통하여 원문복사서비스 이용이 가능합니다.
- 이 논문과 함께 출판된 논문 + 더보기